Saturday 17 October 2026
Export CNTN’s income statement to Excel — free account
Canton Strategic Holdings, Inc.
CNTN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 85.9% and free cash flow fell 600.4%, each against the same quarter a year earlier.
1.70
0.17
−9.09%
Follow CNTN
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 0.04 | 0.11 | 0.14 | 5.84 | 6.03 | 1.54 | 5.29 |
Net Debt/EBITDA |
— | (0.93) | (0.66) | (0.30) | 1.23 | 1.16 | 0.29 | 0.85 |
Debt/Assets |
0.00% | 2,355.50% | 436.53% | 124.32% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | (0.59) | (0.35) | (0.16) | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.46 | 0.45 | 0.49 | 0.77 | 0.78 | 0.89 | 0.45 |
Capex/Depreciation |
— | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
Interest Coverage |
— | (26.48) | (7.34) | (3.86) | (4.32) | (573.04) | (907.58) | (710.46) |
| — | 57.14% | 90.54% | 52.52% | (1,973.27%) | (127.01%) | (233.70%) | (17.99%) | |
| — | (7,459.66%) | (1,440.21%) | (481.53%) | (231.82%) | (105.69%) | (166.32%) | (13.74%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (3.30%) |
Return on Tangible Assets |
— | 140.03% | 99.46% | 56.41% | (152.85%) | (102.06%) | (932.82%) | (254.73%) |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.97 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (1.71) | (63.81) | (63.89) | (217.15) | (83.91) | (8.41) | (2.92) |
Cash per Share |
— | 0.09 | 11.36 | 0.26 | 215.58 | 125.69 | 2.75 | 0.53 |
Shareholders Equity per Share |
— | (3.94) | (219.97) | (275.58) | 183.57 | 104.96 | 1.01 | 12.42 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (3.94) | (219.97) | (275.58) | 183.57 | 104.96 | 1.01 | 12.42 |
Free Cash Flow |
— | (0.71) | (1.08) | (1.09) | (6.56) | (7.30) | (10.90) | (93.70) |
Working Capital |
— | (1.09) | (2.43) | (3.91) | 5.54 | 9.13 | 1.31 | 14.10 |
Capital Expenditures |
— | — | — | — | — | — | — | (77.57) |
Net Current Asset Value |
— | (1.62) | (3.72) | (4.68) | 5.54 | 9.13 | 1.31 | (103.83) |
| Other line items | ||||||||
Quick Ratio |
— | 0.03 | 0.07 | 0.00 | 5.69 | 6.03 | 1.47 | 5.18 |
Depreciation/Fixed assets |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Cash ROIC |
— | 113.80% | 48.17% | 27.80% | (54.40%) | (36.38%) | (224.00%) | (22.58%) |
Accounts Payable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (1.71) | (63.81) | (63.89) | (217.15) | (83.91) | (8.41) | (0.50) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2.42) |
Average Payables |
— | — | — | 0.99 | 1.21 | 0.93 | 1.00 | 1.09 |
Average Assets |
— | 0.02 | 0.17 | 0.46 | 3.66 | 8.82 | 7.33 | 261.43 |
Average Common Equity |
— | (2.67) | (2.67) | (4.20) | 0.43 | 7.34 | 5.22 | 199.62 |
Capex to Sales |
— | — | — | — | — | — | — | 0.00 |
Columns are period end dates